The ZUMA-1 study demonstrated that durable treatment response was associated with low baseline tumor burden, low systemic inflammation, and high CCR7+CD45RA+ T cell product in patients with refractory large B-cell lymphoma treated with axicabtagene ciloleucel (29). This evidence concerns the gene CCR7 and neoplasm.